


# Developing Clinically Relevant Dissolution Specifications (CRDS) for Oral Drug products



## Virtual Webinar Series

January (19th), March (2nd), April (20th), May (18th)

### Free to APS Members

Each session will have at least 2 speakers, including Industry, Academia and Regulatory Colleagues.

There will be plenty of opportunity for Q&A in each webinar.

The first two webinars will set the stage for our seminar series and cover:

### Clinically Relevant Dissolution Specifications: Why, What, and How?

January 19th 2021 – 14.00-15.00

Speakers:

Dr Paul Dickinson –

*SEDA Pharmaceutical Development Services.*

Dr Andreas Abend – *MSD*

### Introduction to PBPK/PBBM: The How and the Why?

March 2nd 2021 – 14.00-15.00

Speakers:

Andrea Moir – *AstraZeneca*

Susan Cole – *MHRA*

### Future sessions will include:

- How to develop CRDS, including case studies from Industry
- Overview of global regulatory trends within CRDS including progress, challenges and emerging opportunities
- Future developments with PBBM/PBPK software packages
- Emerging opportunities within PBPK/PBBM modelling to support CRDS including new research areas

### Registration

Register for one webinar or the full series, by visiting [apsgb.co.uk/event/virtualeventcrds/](https://apsgb.co.uk/event/virtualeventcrds/) Alternatively visit [apsgb.co.uk/join-us/](https://apsgb.co.uk/join-us/) and become a member, so that all APS online events are free of charge.

The webinar series will be of relevance to Industry, Regulators, Specialist Technology Providers and Academic Colleagues.

**The aim is to share and discuss progress and challenges through scientific presentations and Q&A sessions.** The webinars will cover the current state of scientific affairs in the field, emerging trends and identify areas where Industry and Regulators can engage to further harmonise and enable CRDS development moving forwards.

Visit [apsgb.co.uk](https://apsgb.co.uk) for more details.

